{"id":2725,"date":"2026-08-27T13:00:00","date_gmt":"2026-08-27T17:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2725"},"modified":"2026-08-27T19:24:20","modified_gmt":"2026-08-27T23:24:20","slug":"ivosidenib-shows-activity-in-idh1-mutant-myelodysplastic-neoplasms","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2725","title":{"rendered":"Ivosidenib Shows Activity in IDH1-Mutant Myelodysplastic Neoplasms"},"content":{"rendered":"

Consortium:<\/strong> French Myelodysplasia Group (GFM) · Partner:<\/strong> Servier · Drug:<\/strong> Ivosidenib · Trial:<\/strong> IDIOME (Phase II) · Indication:<\/strong> IDH1-Mutant Myelodysplastic Neoplasms · Date:<\/strong> August 25, 2026<\/p>\n

\"20260827_GFM_Servier_IDIOME_Therapeutic_Indications\"<\/p>\n

Summary<\/h4>\n

The French Myelodysplasia Group reported Phase II IDIOME results for single-agent ivosidenib in 48 older adults with IDH1-mutant myelodysplastic neoplasms. Overall response after three cycles was 63.6% in higher-risk disease after azacitidine failure and 78.3% in treatment-naive higher-risk disease. Twelve-month overall survival differed sharply between those cohorts at 18.2% and 91.3%, respectively. The study identifies clinical activity and candidate resistance biomarkers, but its small, nonrandomized cohorts cannot establish comparative benefit or explain the survival separation.<\/p>\n

What Happened<\/h4>\n

IDIOME enrolled three cohorts from 2019 through 2023: higher-risk relapsed or refractory MDS after azacitidine, treatment-naive higher-risk MDS, and lower-risk MDS refractory to erythropoiesis-stimulating agents. All participants received oral ivosidenib 500 mg once daily in 28-day cycles; median age was 76.5 years. Overall response after three cycles was 63.6% (95% CI 40.7-82.8) in the post-azacitidine cohort and 78.3% (95% CI 56.3-92.5) in treatment-naive higher-risk disease. Twelve-month overall survival was 18.2% (95% CI 7.5-44.1) and 91.3% (95% CI 80.5-100), respectively; the lower-risk cohort was described as having no significant toxicities, but the abstract does not provide a complete adverse-event table. A larger baseline IDH1-mutant clone predicted response, whereas TP53 or IDH2 co-mutations were associated with resistance, and molecular clearance was not required for clinical benefit; these associations are exploratory and vulnerable to small subgroup counts, multiple comparisons and disease-risk imbalance.<\/p>\n

Deep Analysis<\/h4>\n

Mutant IDH1 produces the oncometabolite 2-hydroxyglutarate, disrupting epigenetic regulation and differentiation. The strong untreated-cohort response supports biological dependence in an IDH1-selected subset, but the poor post-azacitidine survival emphasizes that target inhibition may not overcome advanced clonal complexity or therapy-resistant disease. The survival contrast can plausibly reflect earlier disease state, treatment history, co-mutation burden and selection rather than a differential drug effect; without a concurrent azacitidine-based control, centralized blinded response review and balanced molecular strata, the study cannot establish that first-line ivosidenib improves survival over current therapy. A biomarker-led development path is attractive for frail patients because an oral single agent may reduce treatment burden, but translation requires randomized evidence against appropriate hypomethylating-agent or combination regimens, prospective validation of co-mutation effects, durability, transfusion outcomes and AML transformation characterization.<\/p>\n

Company and Product Background<\/h4>\n

Myelodysplastic neoplasms are clonal stem-cell disorders characterized by ineffective hematopoiesis, cytopenias and risk of acute myeloid leukemia. IDH1 mutations define a small molecular subset and generate 2-hydroxyglutarate, which impairs normal differentiation through epigenetic dysregulation. Ivosidenib is an oral inhibitor of mutant IDH1, already approved in IDH1-mutant AML in specified settings and in IDH1-mutant cholangiocarcinoma; in MDS, the therapeutic hypothesis is that reducing 2-hydroxyglutarate can restore differentiation without intensive cytotoxic therapy.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Population<\/td>\n48 patients; median age 76.5 years; three clinically distinct cohorts<\/td>\n<\/tr>\n
Higher-Risk Efficacy<\/td>\nORR 63.6% after azacitidine failure and 78.3% when treatment-naive<\/td>\n<\/tr>\n
Survival<\/td>\n12-month OS 18.2% vs. 91.3% across the two higher-risk cohorts (not randomized)<\/td>\n<\/tr>\n
Biomarkers<\/td>\nLarger IDH1 clone predicted response; TP53\/IDH2 co-mutations predicted resistance<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> IDH1 inhibition can provide a lower-burden, biomarker-directed option for selected older patients, particularly before azacitidine failure, supported by response frequency, tolerability and mutation-response relationships.<\/p>\n

Bear case:<\/strong> The apparent first-line advantage mainly reflects disease stage and cohort selection rather than a drug effect, and the study is small and uncontrolled with survival differences that cannot be attributed to ivosidenib specifically.<\/p>\n

InSilens Take<\/h4>\n

IDIOME provides peer-reviewed evidence that oral IDH1 inhibition is active across selected MDS settings and may be most useful before treatment-resistant clonal complexity emerges. It is not a practice-changing survival result: cohort differences, wide intervals and absent randomization prevent a causal comparison.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Mixed · Confidence:<\/strong> High on facts, Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

The French Myelodysplasia Group reported Phase II IDIOME results for single-agent ivosidenib in 48 older adults with IDH1-mutant myelodysplastic neoplasms. Overall response after three cycles was 63.6% in higher-risk disease after azacitidine failure and…<\/p>\n","protected":false},"author":1,"featured_media":2734,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[447,224],"class_list":["post-2725","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-ivosidenib","tag-myelodysplastic-syndrome"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2725"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2725\/revisions"}],"predecessor-version":[{"id":2741,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2725\/revisions\/2741"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2734"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}